News | January 07, 2026
Merck completes acquisition of Cidara Therapeutics
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
India’s pharmaceutical sector stands at a pivotal inflection point
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The approval is supported by data from three pivotal clinical trials
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Subscribe To Our Newsletter & Stay Updated
